Cancer specific lipid targeted peptidomimetics

Patent metadata

Field	Value
Publication number	US-10849875-B2
Application number	US-201615747071-A
Country	US
Kind code	B2
Filing date	Jul 23, 2016
Priority date	Jul 23, 2015
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes.

First claim

What is claimed is:

1. A composition of matter comprising a phosphatidylserine-targeting peptoid selected from the group consisting of 2P3H-PPS1 and 2-4-PPS1.

2. The composition of matter of claim 1 wherein the peptoid is 2P3H-PPS1.

3. The composition of matter of claim 1 wherein the peptoid is 2-4-PPS1.

4. A method of treating a cancer in a patient, said method comprising:
administering to a patient a composition of matter comprising a phosphatidylserine-targeting peptoid selected from the croup consisting of 2P3H-PPS1 and 2-4-PPS1,
wherein the cancer comprises tumor cells expressing phosphatidylserine (PS) on their outer layers.

5. The method of claim 4 , further comprising administering docetaxel to the patient.

6. The method of claim 4 , wherein the peptoid is 2P3H-PPS1.

7. The method of claim 4 , wherein the peptoid is 2-4-PPS1.

8. The method of claim 4 , wherein the cancer comprises at least one of breast cancer, lung cancer, and prostate cancer.

9. The method of claim 4 , wherein the cancer comprises lung cancer.

10. A method of detecting cancer in a patient, said method comprising:
administering to a patient a composition of matter comprising a phosphatidylserine-targeting peptoid conjugated to a fluorescent label, wherein the phosphatidylserine-targeting peptoid is selected from the group consisting of 2P3H-PPS1 and 2-4-PPS1; and
visualizing the location of the fluorescent label in the patient to detect the cancer, wherein the cancer comprises tumor cells expressing phosphatidylserine (PS) on their outer layers.

11. The method of claim 10 wherein the cancer comprises at least one of breast cancer, lung cancer, and prostate cancer.

Assignees

• Univ Houston System
• Univ Of Texas Southwestern Medical Center
• Univ Texas

Inventors

• Udugamasooriya Damith Gomika
• Brekken Rolf A

Classifications

• G01N33/575

  for cancer · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/55

  the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title

• A61K31/343 Primary

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title